Response to McGirr et al.'s Comment on "Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada"

Full copyright for enhanced digital features is owned by Pfizer inc. Article full text The full text of this article can be found here. Provide enhanced digital features for this article If you are an author of this publication and would like to provide additional enhanced digital features for your article then please contact [email protected]. The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content. Other enhanced features include, but are not limited to: • Slide decks • Videos and animations • Audio abstracts • Audio slides </p

Varicella zoster virus infections in Canadian children in the prevaccine era: A hospital-based study

OBJECTIVE: To describe the clinical course of children admitted for varicella zoster virus (VZV) infections to a pediatric hospital before the release of VZV vaccine in Canada

Meningitis due to ampicillin-and chloramphenicol-resistant Haemophilus influenzae type b in Canada. Case report and review

The first report of a case of ampicillin- and chloramphenicol-resistant Haemophilus influenzae type b invasive infection in Canada is described in a four-month-old male with meningitis. He was treated with cefotaxime 200 mg/kg/day divided every 6 h and dexamethasone 0.6 mg/kg/day divided every 6 h, eventually recovering after a complicated course. Follow-up at 21 months showed mild to moderate global developmental delay. While chloramphenicol resistance is rare in North America, a case of meningitis initially unresponsive to ampicillin and chloramphenicol must be considered suspect for resistance. Third generation cephalosporins should be used for resistant cases

Meningitis Due to Ampicillin-and Chloramphenicol-Resistant Haemophilus influenzae Type B in Canada. Case Report and Review

The first report of a case of ampicillin- and chloramphenicol-resistant Haemophilus influenzae type b invasive infection in Canada is described in a four-month-old male with meningitis. He was treated with cefotaxime 200 mg/kg/day divided every 6 h and dexamethasone 0.6 mg/kg/day divided every 6 h, eventually recovering after a complicated course. Follow-up at 21 months showed mild to moderate global developmental delay. While chloramphenicol resistance is rare in North America, a case of meningitis initially unresponsive to ampicillin and chloramphenicol must be considered suspect for resistance. Third generation cephalosporins should be used for resistant cases.Peer Reviewe

Transient in vivo selection of a constitutively cephalosporin resistant Enterobacter cloacae causing ventriculitis

A case of neonatal ventriculitis complicating a ventriculoperitoneal shunt and caused by one strain of Enterobacter cloacae (as shown on pulsed field gel electrophoresis) is presented. Daily ventricular fluid cultures from day 1 to 9 revealed inducible cephalosporin resistance in all isolates except on days 3, 4 and 5 of therapy when isolates were constitutively resistant. This emergence of resistance due to constitutive Bush class 1 beta-lactamase production is an excellent example of the rapid emergence of a predominant strain of bacteria depending on antibiotic selection pressures in vivo. The transient nature of the predominant resistant phenotype may have been due to missing a dose of cefotaxime on day 5 or in vivo factors allowing persistence of sensitive organisms in antibiotic protected sites. Caution is advised in the use of cephalosporins alone for serious Enterobacter species infections. Repeat culture and sensitivity should be done in severe infections that are slow to respond to cephalosporin therapy